Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 24, 2026ESMO OpenOpen Access

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

VEV. Ekström-RydénACA. CarneiroLund UniversityJYJ. YachninKarolinska University Hospital

Discussion

Loading...

Member takes

Implication

Phase I study shows safety of ATOR-1015 in advanced solid cancer, suggesting the need for improved antibody design.

Key Points

  • This study aims to evaluate the safety, tolerability, and preliminary efficacy of the bispecific antibody ATOR-1015 in patients with advanced solid malignancies.
  • Conducted a phase I, multicenter trial
  • Administered ATOR-1015 intravenously every second week
  • Applied a modified 3 + 3 dose-escalation design for treatment.
  • Common adverse events included infusion-related reactions in 50% of patients and 39.3% had stable disease.
  • Notable increases in specific T-cell populations and cytokines were observed post-infusion.
  • Most patients developed anti-drug antibodies, impacting treatment efficacy and safety.

Cite This Study

Ekström-Rydén et al. (2026) studied this question.

synapsesocial.com/papers/69eb0899553a5433e34b383dhttps://doi.org/10.1016/j.esmoop.2026.106068
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hallmarks of Cancer: New Dimensions2022 · 9,963 citations
  2. 2Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy2024 · 49 citations
  3. 3Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden2024 · 22 citations
  4. 4RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties2024 · 8 citations
  5. 5Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma2022 · 728 citations